{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:45:57Z","timestamp":1792755957722,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prognosis of relapsed\/refractory (R\/R) neuroblastoma (NB) is dismal, calling for new therapeutic strategies. Venetoclax (VEN) is a highly selective, potent, orally bioavailable, BCL-2 inhibitor small-molecule that showed a synergistic effect with cyclophosphamide and topotecan (Cy-Topo) in murine NB models. Our aim was to evaluate the feasibility of VEN plus Cy-Topo in children with R\/R NB. Four patients, who had previously failed\u2009&gt;\u20093 lines of treatment, were treated with VEN plus Cy-Topo based on a 28-day schedule in an outpatient setting. BCL-2 expression in immunochemistry on tumor samples at relapse and the <jats:italic>BCL2<\/jats:italic> gene status was evaluated in all patients. The main toxicity was hematological, with grade 4 neutropenia and thrombocytopenia occurring in all courses and leading to transient VEN discontinuation. Grade 3 oral mucositis was observed in 1\/8 courses. No other grade 2\u20134 toxicities were observed. BCL-2 was expressed in all tumors, while no molecular abnormalities in the <jats:italic>BCL-2<\/jats:italic> genes were detected. A stable disease was observed in all patients, without any progression during the study period. VEN plus Cy-Topo is well tolerated, with encouraging results that may be improved by testing the schedule in less advanced patients.<\/jats:p>","DOI":"10.1038\/s41598-023-44993-9","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T14:01:35Z","timestamp":1699365695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series"],"prefix":"10.1038","volume":"13","author":[{"given":"Maria Antonietta","family":"De Ioris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fabozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Del Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Felicia","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Cefalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"Garganese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Stracuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo Maria","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mastronuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"44993_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","volume":"19","author":"B Qiu","year":"2022","unstructured":"Qiu, B. & Matthay, K. K. Advancing therapy for neuroblastoma. Nat. Rev. Clin. Oncol. 19, 515\u2013533 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Suppl 2","key":"44993_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28473","volume":"68","author":"C Chung","year":"2021","unstructured":"Chung, C. et al. Neuroblastoma. Pediatr. Blood Cancer 68(Suppl 2), e28473 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"44993_CR3","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1002\/cncr.30934","volume":"123","author":"WB London","year":"2017","unstructured":"London, W. B. et al. Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children\u2019s Oncology Group early-phase trials. Cancer 123, 4914\u20134923 (2017).","journal-title":"Cancer"},{"key":"44993_CR4","first-page":"1","volume":"42","author":"SG Du-Bois","year":"2022","unstructured":"Du-Bois, S. G., Macy, M. E. & Henderson, T. O. High-risk and relapsed neuroblastoma: Toward more cures and better outcomes. Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet. 42, 1\u201313 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"44993_CR5","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","volume":"30","author":"MS Davids","year":"2012","unstructured":"Davids, M. S. & Letai, A. Targeting the B-cell lymphoma\/leukemia 2 family in cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30, 3127\u20133135 (2012).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"44993_CR6","doi-asserted-by":"publisher","first-page":"27946","DOI":"10.18632\/oncotarget.8547","volume":"7","author":"LT Bate-Eya","year":"2016","unstructured":"Bate-Eya, L. T. et al. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget 7, 27946\u201327958 (2016).","journal-title":"Oncotarget"},{"key":"44993_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12885-016-2129-0","volume":"16","author":"R Tanos","year":"2016","unstructured":"Tanos, R., Karmali, D., Nalluri, S. & Goldsmith, K. C. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma. BMC Cancer 16, 97 (2016).","journal-title":"BMC Cancer"},{"issue":"48","key":"44993_CR8","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.ejca.2012.01.037","volume":"1990","author":"F Lamers","year":"2012","unstructured":"Lamers, F. et al. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. Eur. J. Cancer Oxf. Engl. 1990(48), 3093\u20133103 (2012).","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"44993_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"44993_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","volume":"21","author":"SE Karol","year":"2020","unstructured":"Karol, S. E. et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: A phase 1, dose-escalation study. Lancet Oncol. 21, 551\u2013560 (2020).","journal-title":"Lancet Oncol."},{"key":"44993_CR11","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat, V. A. et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 11, 1440\u20131453 (2021).","journal-title":"Cancer Discov."},{"key":"44993_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cancers14010150","volume":"14","author":"A Gibson","year":"2021","unstructured":"Gibson, A. et al. Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers 14, 150 (2021).","journal-title":"Cancers"},{"key":"44993_CR13","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-20-0710","volume":"20","author":"KM Dalton","year":"2021","unstructured":"Dalton, K. M. et al. Venetoclax-based rational combinations are effective in models of MYCN-amplified neuroblastoma. Mol. Cancer Ther. 20, 1400\u20131411 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"44993_CR14","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2217\/fon-2018-0121","volume":"14","author":"AE Place","year":"2018","unstructured":"Place, A. E. et al. Accelerating drug development in pediatric cancer: A novel Phase I study design of venetoclax in relapsed\/refractory malignancies. Future Oncol. Lond. Engl. 14, 2115\u20132129 (2018).","journal-title":"Future Oncol. Lond. Engl."},{"key":"44993_CR15","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.1200\/JCO.2020.38.15_suppl.10524","volume":"38","author":"KC Goldsmith","year":"2020","unstructured":"Goldsmith, K. C. et al. The first report of pediatric patients with solid tumors treated with venetoclax. J. Clin. Oncol. 38, 10524\u201310524 (2020).","journal-title":"J. Clin. Oncol."},{"key":"44993_CR16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"44993_CR17","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","volume":"35","author":"JR Park","year":"2017","unstructured":"Park, J. R. et al. Revisions to the international neuroblastoma response criteria: A consensus statement from the national cancer institute clinical trials planning meeting. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 35, 2580\u20132587 (2017).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"44993_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00259-016-3516-0","volume":"44","author":"V Lewington","year":"2017","unstructured":"Lewington, V. et al. 123I-mIBG scintigraphy in neuroblastoma: Development of a SIOPEN semi-quantitative reporting, method by an international panel. Eur. J. Nucl. Med. Mol. Imaging 44, 234\u2013241 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"44993_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.2010.31.7107","volume":"29","author":"R Bagatell","year":"2011","unstructured":"Bagatell, R. et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children\u2019s Oncology Group study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29, 208\u2013213 (2011).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"44993_CR20","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2009.27.5016","volume":"28","author":"WB London","year":"2010","unstructured":"London, W. B. et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children\u2019s Oncology Group study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28, 3808\u20133815 (2010).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"50","key":"44993_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2013.08.012","volume":"1990","author":"A Di Giannatale","year":"2014","unstructured":"Di Giannatale, A. et al. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. Eur. J. Cancer Oxf. Engl. 1990(50), 170\u2013177 (2014).","journal-title":"Eur. J. Cancer Oxf. Engl."},{"issue":"51","key":"44993_CR22","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.ejca.2015.07.023","volume":"1990","author":"MJ Zhou","year":"2015","unstructured":"Zhou, M. J. et al. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur. J. Cancer Oxf. Engl. 1990(51), 2465\u20132472 (2015).","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"44993_CR23","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1200\/JCO.2010.34.3392","volume":"29","author":"WB London","year":"2011","unstructured":"London, W. B. et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group project. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29, 3286\u20133292 (2011).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"44993_CR24","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1200\/JCO.20.00203","volume":"38","author":"R Mody","year":"2020","unstructured":"Mody, R. et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: A report from the children\u2019s oncology group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 38, 2160\u20132169 (2020).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"44993_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01273","author":"BJ Lerman","year":"2022","unstructured":"Lerman, B. J. et al. Progression-free survival and patterns of response in patients with relapsed high-risk neuroblastoma treated with irinotecan\/temozolomide\/dinutuximab\/granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.22.01273 (2022).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"44993_CR26","first-page":"E142","volume":"5","author":"EG Greengard","year":"2018","unstructured":"Greengard, E. G. Molecularly targeted therapy for neuroblastoma. Child. Basel Switz. 5, E142 (2018).","journal-title":"Child. Basel Switz."},{"issue":"157","key":"44993_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejca.2021.08.022","volume":"1990","author":"ADJ Pearson","year":"2021","unstructured":"Pearson, A. D. J. et al. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur. J. Cancer Oxf. Engl. 1990(157), 198\u2013213 (2021).","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"44993_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01630","author":"T Flaadt","year":"2023","unstructured":"Flaadt, T. et al. Anti-GD2 antibody dinutuximab beta and low-dose interleukin 2 after haploidentical stem-cell transplantation in patients with relapsed neuroblastoma: A multicenter, Phase I\/II trial. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.22.01630 (2023).","journal-title":"J. Clin. Oncol."},{"key":"44993_CR29","first-page":"42","volume":"72","author":"S Krajewski","year":"1995","unstructured":"Krajewski, S., Chatten, J., Hanada, M. & Reed, J. C. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein. Lab. Investig. J. Tech. Methods Pathol. 72, 42\u201354 (1995).","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"44993_CR30","first-page":"1543","volume":"143","author":"VP Castle","year":"1993","unstructured":"Castle, V. P. et al. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol. 143, 1543\u20131550 (1993).","journal-title":"Am. J. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44993-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T14:04:59Z","timestamp":1699365899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44993-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44993"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44993-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19295"}}